---
title: Assessment of VAC-3S Therapeutic Properties When Combined With Standard ART in the Course of HIV-1 Infection
nct_id: NCT02041247
overall_status: UNKNOWN
phase: PHASE2
sponsor: InnaVirVax
study_type: INTERVENTIONAL
primary_condition: HIV
countries: France, Germany, Spain
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02041247.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02041247"
ct_last_update_post_date: 2016-06-17
last_seen_at: "2026-05-12T07:30:13.714Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Assessment of VAC-3S Therapeutic Properties When Combined With Standard ART in the Course of HIV-1 Infection

**Official Title:** Assessment of VAC-3S Therapeutic Properties When Combined With Standard Antiretroviral Therapy (ART) in the Course of HIV-1 Infection. A European, Randomized, Double Blind Placebo-controlled Phase II Study

**NCT ID:** [NCT02041247](https://clinicaltrials.gov/study/NCT02041247)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 90
- **Lead Sponsor:** InnaVirVax
- **Conditions:** HIV
- **Start Date:** 2014-01
- **Completion Date:** 2016-11
- **CT.gov Last Update:** 2016-06-17

## Brief Summary

The purpose of this study is to evaluate the protective effect of VAC-3S in controlled HIV patients receiving standard of care antiretroviral treatment.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 60 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Documented HIV-1 infection,
2. Adults \> 18 and \< 60 years of age,
3. Able and willing to comply with the protocol, including availability for all scheduled study visits,
4. Provided a signed written informed consent,
5. Meets study screening physical, medical history and laboratory assessments (defined below),
6. On stable antiretroviral therapy that is consistent with the current standard of care for at least 12 months prior to study screening,
7. Plasma HIV RNA \< 50 cps/mL during the previous 12 months,
8. CD4+ T cell count at screening \> 200 and \< 500 cells/mm3,
9. Adequate hematology, biochemistry, and metabolic blood tests defined as being less than grade 2 according to the Division of AIDS Adverse Events (See Appendix 23.1), except for the numeration of CD4 and for the numeration of lymphocytes,
10. Adequate hepatic and renal function defined as being less than Grade 2 according to the Division of AIDS Adverse Events (See Appendix 23.1),
11. Female patients of childbearing age with one documented negative blood pregnancy tests between Screening and Visit 1/Month 0; Female patient of childbearing potential must be receiving two forms of effective contraception and must be willing to use them throughout the study duration. These include oral, transdermal, systemic or implant contraception birth control, intra-uterine devices (IUD), abstinence and double barrier method such as diaphragm with spermicidal gel or other recommended double barrier method,
12. Affiliated with the National Medical Insurance System,
13. Believed by investigator to be able and willing to comply with the requirements of the study protocol and will be available for all scheduled visits at the study site.

Exclusion Criteria:

1. Not meeting all of the inclusion criteria listed above,
2. Administration of any investigational drug or device within 28 days prior to screening,
3. Prior history of an AIDS-defining event in the past 5 years,
4. Active co-infection with either Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV) or any other active viral hepatitis co-infection,
5. Any acute or clinically significant infections within the past month,
6. Known allergy or intolerance to components of VAC-3S as documented through medical records or via patient interview,
7. Chronic active liver disease as documented by any of the following laboratory assessments: ultrasound, clinical assessment, liver biopsy or equivalent non-invasive methods,
8. Receipt of any known vaccinations within the past 1 month prior to screening,
9. Receipt of any agent in the past 12 months that exerts a known immunological effect (e.g. includes but not limited to IL-2, IL-7, growth hormone…),
10. Patients with Insulin Dependent Diabetes Mellitus, patients receiving anti-diabetic treatment, anticoagulants (excluding daily "baby-dose" aspirin) or daily NSAIDs within one week of study enrollment,
11. Receipt of any contraindicated medications listed in Appendix 23.2,
12. History of or active auto-immune disease,
13. Acute or chronic psychiatric conditions which in the opinion of the investigator would need continual psychological support and/or medications incompatible with study participation,
14. Patients with contraindications to intramuscular injections including, but not limited to, patients with thrombocytopenia and/or anomalies of the coagulation system,
15. Any uncontrolled chronic or acute condition that in the opinion of the investigator would compromise safety of the patient or the ability to properly administer the study.
```

## Arms

- **VAC-3S 16µg/administration** (ACTIVE_COMPARATOR) — VAC-3S 16µg/ml administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.
- **VAC-3S Placebo** (PLACEBO_COMPARATOR) — VAC-3S placebo administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.
- **VAC-3S 32 µg/administration** (ACTIVE_COMPARATOR) — VAC-3S 32µg/ml administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.
- **VAC-3S 64 µg/administration** (ACTIVE_COMPARATOR) — VAC-3S 64µg/ml administered every 4 weeks for 3 months without maintenance vaccination.

## Interventions

- **VAC-3S** (BIOLOGICAL) — VAC-3S is administered via intra-muscular route in the arm.

## Primary Outcomes

- **anti-3S antibodies titer** _(time frame: From D0 to week 24)_

## Secondary Outcomes

- **tolerance to 6 vaccinations of VAC-3S** _(time frame: From D0 to week 72)_
- **blood inflammatory marker concentrations** _(time frame: From D0 to week 72)_
- **immunogenic characteristics of VAC-3S** _(time frame: From D0 to week 72)_
- **lymphocyte phenotype markers** _(time frame: From D0 to week 72)_
- **secondary virological effects** _(time frame: From D0 to week 72)_

## Locations (12)

- Hôpital Sud Francilien, Corbeil-Essonne, France
- Hôpital de la Croix Rousse, Lyon, France
- Hôpital Gui de Chauliac, Montpellier, France
- Hôpital Saint-Antoine, Paris, France
- Hôpital Pitié Salpêtrière, Paris, France
- Hôpital Cochin Saint Vincent de Paul, Paris, France
- Hôpital Européen Georges Pompidou, Paris, France
- Hôpital Bichat - Claude Bernard, Paris, France
- Hôpital Tenon, Paris, France
- Jürgen Rockstroh, Bonn, Germany
- Gerd Fätkenheuer, Cologne, Germany
- Hospital Clinic University of Barcelona, Barcelona, Spain

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.hôpital sud francilien|corbeil-essonne||france` — added _(2026-05-12)_
- `locations.hôpital de la croix rousse|lyon||france` — added _(2026-05-12)_
- `locations.hôpital gui de chauliac|montpellier||france` — added _(2026-05-12)_
- `locations.hôpital saint-antoine|paris||france` — added _(2026-05-12)_
- `locations.hôpital pitié salpêtrière|paris||france` — added _(2026-05-12)_
- `locations.hôpital cochin saint vincent de paul|paris||france` — added _(2026-05-12)_
- `locations.hôpital européen georges pompidou|paris||france` — added _(2026-05-12)_
- `locations.hôpital bichat - claude bernard|paris||france` — added _(2026-05-12)_
- `locations.hôpital tenon|paris||france` — added _(2026-05-12)_
- `locations.jürgen rockstroh|bonn||germany` — added _(2026-05-12)_
- `locations.gerd fätkenheuer|cologne||germany` — added _(2026-05-12)_
- `locations.hospital clinic university of barcelona|barcelona||spain` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02041247.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02041247*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*